Hints and tips:
...SmithKline Beecham (now part of GSK) pulled its successful Lyme disease vaccine in the early 2000s amid rising anti-vaccine sentiment....
...Beecham to create GSK....
...A veteran of the pharmaceuticals industry, he experienced a big merger while working for SmithKline Beecham when it combined with Glaxo Wellcome in 2000....
...That was what happened in the last big round of consolidation, around the turn of the millennium, through Glaxo Wellcome’s merger with SmithKline Beecham and Pfizer’s with Warner-Lambert and Wyeth....
...I was an investor in Glaxo Wellcome and SmithKline Beecham through most of the 1990s, before their merger into one entity....
...He notes that Allergan was spun out of SmithKline in 1989 when it merged with Beecham....
...A Pfizer-AstraZeneca deal would rival the $74bn merger between GlaxoWellcome and SmithKline Beecham in 2000 as the biggest in industry history, and outstrip Pfizer’s own record $68bn acquisition of Wyeth...
...An MBA at Cranfield followed, and he landed a marketing job at SmithKline Beecham as assistant product manager of Instant Horlicks, a powdered drink....
...As Glaxo Wellcome chief, he oversaw its merger with SmithKline Beecham in 2000, and stepped down in 2002 at the age of 60....
...He was also finance director at BG Group and chief financial officer at SmithKline Beecham, which merged with Glaxo Wellcome in 2000 to createGlaxoSmithKline....
...In 1999, the ranking was BP, BT, Vodafone, HSBC and GlaxoSmithKline (Glaxo Wellcome only formally merged with SmithKline Beecham in 2000)....
...As the Glaxo Wellcome merger with SmithKline Beecham and the acquisition of NatWest by the Royal Bank of Scotland demonstrated, these effects really do exist in the real world....
...In 1999, Smithkline Beecham held a 29 per cent stake in the group. Quest’s laboratories provide test for cancers, cardiovascular diseases, thyroid disorders, and infectious diseases....
...GSK, formed by a merger between Glaxo Wellcome and SmithKline Beecham in 2000, knows size alone is no cure-all....
...Beecham in 1988....
...The company has evolved since Mr Garnier sparked a wave of industry consolidation in 2000, when he took SmithKline Beecham into what was then the UK’s largest merger, with Glaxo Wellcome....
...They gathered data to help make the case to the SmithKline board to fund their general adjuvant-based approach....
...Lisbon’s growing stature as an international pharmaceutical research centre – with global giants such as SmithKline Beecham setting up large operations – has also helped....
...Today, on Mr Yamada’s last day as head of research and development at GSK and a decade after he first became an employee of SmithKline Beecham, things look rather brighter....
...Ironically, before the merger, just as SmithKline Beecham had been a pioneer in offering discounted prices for vaccines in the developing world, so GlaxoWellcome was already offering substantial regional...
...Jean-Pierre Garnier recalls his concern when he took over as chief executive of GSK, following its creation from the merger of Glaxo Wellcome and SmithKline Beecham in 2000, and began to study in detail...
International Edition